Influence of a novel inhibitor (UM8190) of prolylcarboxypeptidase (PRCP) on appetite and thrombosis

Current Medicinal Chemistry

Volumn 19, Issue 24, 2012, Pages 4194-4206

  Rabey, F M ^a   Gadepalli, R S V S ^a   Diano, S ^c   Cheng, Q ^b   Tabrizian, T ^a   Gailani, D ^b   Rimoldi, J M ^a   Shariat Madar, Z ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alpha MSH; Anorexigenic; Factor XII; Obesity; Prolylcarboxypeptidase; Thrombosis

Indexed keywords

1,10 PHENANTHROLINE; ANGIOTENSIN II; ANOREXIGENIC AGENT; ANTICOAGULANT AGENT; BRADYKININ; CARBOXYPEPTIDASE; N DODECYL 1 (PYRROLIDINE 2 CARBONYL) PYRROLIDINE 2 CARBOXAMIDE; PEPTIDE HYDROLASE INHIBITOR; PREKALLIKREIN; PROLINE CARBOXYPEPTIDASE; SERINE PROTEINASE; SOYBEAN TRYPSIN INHIBITOR; UM 8190; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; APPETITE; ARTICLE; CAROTID ARTERY THROMBOSIS; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; FOOD INTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PULMONARY ARTERY; VASCULAR ENDOTHELIUM;

ANIMALS; APPETITE; APPETITE DEPRESSANTS; BRADYKININ; CARBOXYPEPTIDASES; CELL LINE; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; HUMANS; MICE; MICE, INBRED C57BL; NITRIC OXIDE; PREKALLIKREIN; PROLINE; PROTEASE INHIBITORS; THROMBOSIS;

EID: 84866648508     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712802430036     Document Type: Article

References (61)

1. Das, U. N.; Rao, A. A. Gene expression profile in obesity and type 2 diabetes mellitus. Lipids Health Dis. 2007, 6, 35.
2. Leiter, L. A.; Lewanczuk, R. Z. Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition. Am. J. Hypertens. 2005, 18 (1), 121-128.
3. Shariat-Madar, B.; Kolte, D.; Verlangieri, A.; Shariat-Madar, Z. Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment. Diabetes Metab Syndr. Obes. 2010, 3, 67-78.
4. Brzoska, T.; Luger, T. A.; Maaser, C.; Abels, C.; Bohm, M. Alphamelanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr. Rev. 2008, 29 (5), 581-602.
5. Luger, T. A.; Schwarz, T.; Kalden, H.; Scholzen, T.; Schwarz, A.; Brzoska, T. Role of epidermal cell-derived alpha-melanocyte stimulating hormone in ultraviolet light mediated local immunosuppression. Ann. N. Y. Acad. Sci. 1999, 885, 209-216.
6. Raap, U.; Brzoska, T.; Sohl, S.; Path, G.; Emmel, J.; Herz, U.; Braun, A.; Luger, T.; Renz, H. Alpha-melanocyte-stimulating hormone inhibits allergic airway inflammation. J. Immunol. 2003, 171 (1), 353-359.
7. Shimakura, S.; Miura, T.; Maruyama, K.; Nakamachi, T.; Uchiyama, M.; Kageyama, H.; Shioda, S.; Takahashi, A.; Matsuda, K. Alpha-melanocytestimulating hormone mediates melanin-concentrating hormone-induced anorexigenic action in goldfish. Horm. Behav. 2008, 53 (2), 323-328.
8. Kim, M. S.; Rossi, M.; Abusnana, S.; Sunter, D.; Morgan, D. G.; Small, C. J.; Edwards, C. M.; Heath, M. M.; Stanley, S. A.; Seal, L. J.; Bhatti, J. R.; Smith, D. M.; Ghatei, M. A.; Bloom, S. R. Hypothalamic localization of the feeding effect of agouti-related peptide and alpha-melanocyte-stimulating hormone. Diabetes 2000, 49 (2), 177-182.
9. Costa, J. L.; Hochgeschwender, U.; Brennan, M. The role of melanocytestimulating hormone in insulin resistance and type 2 diabetes mellitus. Treat. Endocrinol. 2006, 5 (1), 7-13.
10. Hoggard, N.; Rayner, D. V.; Johnston, S. L.; Speakman, J. R. Peripherally administered [Nle4,D-Phe7]-alpha-melanocyte stimulating hormone increases resting metabolic rate, while peripheral agouti-related protein has no effect, in wild type C57BL/6 and ob/ob mice. J. Mol. Endocrinol. 2004, 33 (3), 693-703.
11. Huszar, D.; Lynch, C. A.; Fairchild-Huntress, V.; Dunmore, J. H.; Fang, Q.; Berkemeier, L. R.; Gu, W.; Kesterson, R. A.; Boston, B. A.; Cone, R. D.; Smith, F. J.; Campfield, L. A.; Burn, P.; Lee, F. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997, 88 (1), 131-141.
12. Dubern, B.; Clement, K.; Pelloux, V.; Froguel, P.; Girardet, J. P.; Guy-Grand, B.; Tounian, P. Mutational analysis of melanocortin-4 receptor, agouti-related protein, and alpha-melanocyte-stimulating hormone genes in severely obese children. J. Pediatr. 2001, 139 (2), 204-209.
13. Wirth, M. M.; Olszewski, P. K.; Yu, C.; Levine, A. S.; Giraudo, S. Q. Paraventricular hypothalamic alpha-melanocyte-stimulating hormone and MTII reduce feeding without causing aversive effects. Peptides 2001, 22 (1), 129-134.
14. D'Agostino, G.; Diano, S. Alpha-melanocyte stimulating hormone: production and degradation. J Mol. Med 2010, 88 (12), 1195-1201.
15. Wallingford, N.; Perroud, B.; Gao, Q.; Coppola, A.; Gyengesi, E.; Liu, Z. W.; Gao, X. B.; Diament, A.; Haus, K. A.; Shariat-Madar, Z.; Mahdi, F.; Wardlaw, S. L.; Schmaier, A. H.; Warden, C. H.; Diano, S. Prolylcarboxypeptidase regulates food intake by inactivating alpha-MSH in rodents. J. Clin. Invest 2009, 119 (8), 2291-2303.
16. Kolte, D.; Bryant, J.; Holsworth, D.; Wang, J.; Akbari, P.; Gibson, G.; Shariat-Madar, Z. Biochemical characterization of a novel high-affinity and specific plasma kallikrein inhibitor. Br. J. Pharmacol. 2010.
17. Alexander, S. P.; Mathie, A.; Peters, J. A. Guide to Receptors and Channels (GRAC), 4rd edition. Br. J. Pharmacol. 2009, 158 Suppl 1, S1-254.
18. Chajkowski, S. M.; Mallela, J.; Watson, D. E.; Wang, J.; McCurdy, C. R.; Rimoldi, J. M.; Shariat-Madar, Z. Highly selective hydrolysis of kinins by recombinant prolylcarboxypeptidase. Biochem. Biophys. Res. Commun. 2011, 405(3), 338-43.
19. Moreira, C. R.; Schmaier, A. H.; Mahdi, F.; da, M. G.; Nader, H. B.; Shariat-Madar, Z. Identification of prolylcarboxypeptidase as the cell matrixassociated prekallikrein activator. FEBS Lett. 2002, 523 (1-3), 167-170.
20. Zhao, Y.; Qiu, Q.; Mahdi, F.; Shariat-Madar, Z.; Rojkjaer, R.; Schmaier, A. H. Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO formation. Am. J. Physiol Heart Circ. Physiol 2001, 280 (4), H1821-H1829.
21. Erdos, E. G.; SLOANE, E. M. An enzyme in human blood plasma that inactivates bradykinin and kallidins. Biochem. Pharmacol. 1962, 11, 585-592.
22. Deddish, P. A.; Skidgel, R. A.; Kriho, V. B.; Li, X. Y.; Becker, R. P.; Erdos, E. G. Carboxypeptidase M in Madin-Darby canine kidney cells. Evidence that carboxypeptidase M has a phosphatidylinositol glycan anchor. J. Biol. Chem. 1990, 265 (25), 15083-15089.
23. Schatteman, K.; Goossens, F.; Leurs, J.; Verkerk, R.; Scharpe, S.; Michiels, J. J.; Hendriks, D. Carboxypeptidase U at the interface between coagulation and fibrinolysis. Clin. Appl. Thromb. Hemost. 2001, 7 (2), 93-101.
24. Schatteman, K. A.; Goossens, F. J.; Scharpe, S. S.; Hendriks, D. F. Activation of plasma procarboxypeptidase U in different mammalian species points to a conserved pathway of inhibition of fibrinolysis. Thromb. Haemost. 1999, 82 (6), 1718-1721.
25. Mallela, J.; Perkins, R.; Yang, J.; Pedigo, S.; Rimoldi, J. M.; Shariat-Madar, Z. The functional importance of the N-terminal region of human prolylcarboxypeptidase. Biochem. Biophys. Res. Commun. 2008, 374 (4), 635-640.
26. Ngo, M. L.; Mahdi, F.; Kolte, D.; Shariat-Madar, Z. Upregulation of prolylcarboxypeptidase (PRCP) in lipopolysaccharide (LPS) treated endothelium promotes inflammation. J. Inflamm. (Lond) 2009, 6, 3.
27. Shu, I. W.; Lindenberg, D. L.; Mizuno, T. M.; Roberts, J. L.; Mobbs, C. V. The fatty acid synthase inhibitor cerulenin and feeding, like leptin, activate hypothalamic pro-opiomelanocortin (POMC) neurons. Brain Res. 2003, 985 (1), 1-12.
28. Zhou, C.; Garcia-Calvo, M.; Pinto, S.; Lombardo, M.; Feng, Z.; Bender, K.; Pryor, K. D.; Bhatt, U. R.; Chabin, R. M.; Geissler, W. M.; Shen, Z.; Tong, X.; Zhang, Z.; Wong, K. K.; Roy, R. S.; Chapman, K. T.; Yang, L.; Xiong, Y. Design and synthesis of prolylcarboxypeptidase (PrCP) inhibitors to validate PrCP as a potential target for obesity. J. Med. Chem. 2010, 53 (19), 7251-7263.
29. Cheng, Q.; Tucker, E. I.; Pine, M. S.; Sisler, I.; Matafonov, A.; Sun, M. F.; White-Adams, T. C.; Smith, S. A.; Hanson, S. R.; McCarty, O. J.; Renne, T.; Gruber, A.; Gailani, D. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood 2010, 116 (19), 3981-3989.
30. Renne, T.; Pozgajova, M.; Gruner, S.; Schuh, K.; Pauer, H. U.; Burfeind, P.; Gailani, D.; Nieswandt, B. Defective thrombus formation in mice lacking coagulation factor XII. J. Exp. Med. 2005, 202 (2), 271-281.
31. Wang, X.; Smith, P. L.; Hsu, M. Y.; Gailani, D.; Schumacher, W. A.; Ogletree, M. L.; Seiffert, D. A. Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. J Thromb. Haemost. 2006, 4 (9), 1982-1988.
32. Jackman, H. L.; Tan, F.; Schraufnagel, D.; Dragovic, T.; Dezso, B.; Becker, R. P.; Erdos, E. G. Plasma membrane-bound and lysosomal peptidases in human alveolar macrophages. Am. J Respir. Cell Mol. Biol. 1995, 13 (2), 196-204.
33. Kumamoto, K.; Stewart, T. A.; Johnson, A. R.; Erdos, E. G. Prolylcarboxypeptidase (angiotensinase C) in human lung and cultured cells. J. Clin. Invest 1981, 67 (1), 210-215.
34. Shariat-Madar, Z.; Mahdi, F.; Schmaier, A. H. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol. Chem. 2002, 277 (20), 17962-17969.
35. Shariat-Madar, Z.; Mahdi, F.; Schmaier, A. H. Recombinant prolylcarboxypeptidase activates plasma prekallikrein. Blood 2004, 103 (12), 4554-4561.
36. Wuepper, K. D.; Cochrane, C. G. Plasma prekallikrein: isolation, characterization, and mechanism of activation. J Exp. Med 1972, 135 (1), 1-20.
37. Tan, F.; Morris, P. W.; Skidgel, R. A.; Erdos, E. G. Sequencing and cloning of human prolylcarboxypeptidase (angiotensinase C). Similarity to both serine carboxypeptidase and prolylendopeptidase families. J. Biol. Chem. 1993, 268 (22), 16631-16638.
38. Wang, L.; Feng, Y.; Zhang, Y.; Zhou, H.; Jiang, S.; Niu, T.; Wei, L. J.; Xu, X.; Xu, X.; Wang, X. Prolylcarboxypeptidase gene, chronic hypertension, and risk of preeclampsia. Am. J. Obstet. Gynecol. 2006, 195 (1), 162-171.
39. Zhang, Y.; Hong, X. M.; Xing, H. X.; Li, J. P.; Huo, Y.; Xu, X. P. E112D polymorphism in the prolylcarboxypeptidase gene is associated with blood pressure response to benazepril in Chinese hypertensive patients. Chin Med J (Engl) 2009, 122 (20), 2461-2465.
40. Zhu, L.; Carretero, O. A.; Liao, T. D.; Harding, P.; Li, H.; Sumners, C.; Yang, X. P. Role of prolylcarboxypeptidase in angiotensin II type 2 receptormediated bradykinin release in mouse coronary artery endothelial cells. Hypertension 2010, 56 (3), 384-390.
41. Diano, S. New aspects of melanocortin signaling: a role for PRCP in alpha-MSH degradation. Front Neuroendocrinol. 2011, 32 (1), 70-83.
42. Catania, A.; Delgado, R.; Airaghi, L.; Cutuli, M.; Garofalo, L.; Carlin, A.; Demitri, M. T.; Lipton, J. M. alpha-MSH in systemic inflammation. Central and peripheral actions. Ann. N Y. Acad. Sci. 1999, 885, 183-187.
43. Caruso, C.; Mohn, C.; Karara, A. L.; Rettori, V.; Watanobe, H.; Schioth, H. B.; Seilicovich, A.; Lasaga, M. Alpha-melanocyte-stimulating hormone through melanocortin-4 receptor inhibits nitric oxide synthase and cyclooxygenase expression in the hypothalamus of male rats. Neuroendocrinology 2004, 79 (5), 278-286.
44. Dong, Y.; Cao, J.; Wang, H.; Zhang, J.; Zhu, Z.; Bai, R.; Hao, H.; He, X.; Fan, R.; Dong, C. Nitric oxide enhances the sensitivity of alpaca melanocytes to respond to alpha-melanocyte-stimulating hormone by up-regulating melanocortin-1 receptor. Biochem. Biophys. Res. Commun. 2010, 396 (4), 849-853.
45. Catania, A.; Lipton, J. M. The neuropeptide alpha-melanocyte-stimulating hormone: a key component of neuroimmunomodulation. Neuroimmunomodulation. 1994, 1 (2), 93-99.
46. Hartmeyer, M.; Scholzen, T.; Becher, E.; Bhardwaj, R. S.; Schwarz, T.; Luger, T. A. Human dermal microvascular endothelial cells express the melanocortin receptor type 1 and produce increased levels of IL-8 upon stimulation with alpha-melanocyte-stimulating hormone. J. Immunol. 1997, 159 (4), 1930-1937.
47. Wong, K. Y.; Rajora, N.; Boccoli, G.; Catania, A.; Lipton, J. M. A potential mechanism of local anti-inflammatory action of alpha- melanocytestimulating hormone within the brain: modulation of tumor necrosis factoralpha production by human astrocytic cells. Neuroimmunomodulation. 1997, 4 (1), 37-41.
48. Star, R. A.; Rajora, N.; Huang, J.; Stock, R. C.; Catania, A.; Lipton, J. M. Evidence of autocrine modulation of macrophage nitric oxide synthase by alpha-melanocyte-stimulating hormone. Proc. Natl. Acad. Sci. U. S. A 1995, 92 (17), 8016-8020.
49. Hill, C.; Dunbar, J. C. The effects of acute and chronic alpha melanocyte stimulating hormone (alphaMSH) on cardiovascular dynamics in conscious rats. Peptides 2002, 23 (9), 1625-1630.
50. Yoshimoto, T.; Kawahara, K.; Matsubara, F.; Kado, K.; Tsuru, D. Comparison of inhibitory effects of prolinal-containing peptide derivatives on prolyl endopeptidases from bovine brain and Flavobacterium. J Biochem. 1985, 98 (4), 975-979.
51. Shiratori, K.; Ohgami, K.; Ilieva, I. B.; Koyama, Y.; Yoshida, K.; Ohno, S. Inhibition of endotoxin-induced uveitis and potentiation of cyclooxygenase-2 protein expression by alpha-melanocyte-stimulating hormone. Invest Ophthalmol. Vis. Sci. 2004, 45 (1), 159-164.
52. Hoene, M.; Weigert, C. The role of interleukin-6 in insulin resistance, body fat distribution and energy balance. Obes. Rev. 2008, 9 (1), 20-29.
53. Mayerle, J. A novel role for leucocytes in determining the severity of acute pancreatitis. Gut 2009, 58 (11), 1440-1441.
54. Chen, X.; Ji, B.; Han, B.; Ernst, S. A.; Simeone, D.; Logsdon, C. D. NFkappaB activation in pancreas induces pancreatic and systemic inflammatory response. Gastroenterology 2002, 122 (2), 448-457.
55. Adams G.N; Zhou Y; Larusch G; Nieman M; Hoit B; Jacobs G; Yu X; Mahdi F; Shariat-Madar Z; Okada Y.; Schmaier A.H. Prolylcarboxypeptidase murine hypomorphs are hypertensive and prothrombotic. Journal of Thrombosis and Haemostasis 7 Supplement 2, XXII ISTH Congress, Abstract OC-MO-128. 2009. Ref Type: Abstract
56. Witherow, F. N.; Dawson, P.; Ludlam, C. A.; Webb, D. J.; Fox, K. A.; Newby, D. E. Bradykinin receptor antagonism and endothelial tissue plasminogen activator release in humans. Arterioscler. Thromb. Vasc. Biol. 2003, 23 (9), 1667-1670.
57. Revenko, A. S.; Gao, D.; Crosby, J. R.; Bhattacharjee, G.; Zhao, C.; May, C.; Gailani, D.; Monia, B. P.; Macleod, A. R. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood 2011.
58. Ma, L.; Fogo, A. B. Role of angiotensin II in glomerular injury. Semin. Nephrol. 2001, 21 (6), 544-553.
59. Goto, Y.; rai-Otsuki, S.; Tachibana, Y.; Ichikawa, D.; Ozaki, S.; Takahashi, H.; Iwasawa, Y.; Okamoto, O.; Okuda, S.; Ohta, H.; Sagara, T. Identification of a novel spiropiperidine opioid receptor-like 1 antagonist class by a focused library approach featuring 3D-pharmacophore similarity. J Med Chem. 2006, 49 (3), 847-849.
60. Zhang, R.; Madalengoitia, J. S. Conformational stability of proline oligomers. Tetrahedron Letters 1996, 37 (35), 6235-6238.
61. De, P. M.; Moretto, A.; Crisma, M.; Peggion, C.; Formaggio, F.; Kaptein, B.; Broxterman, Q. B.; Toniolo, C. Is the backbone conformation of C(alpha)-methyl proline restricted to a single region? Chemistry 2009, 15 (32), 8015-8025.